Novan’s Drug Substance Demonstrates Inhibition of HPV-18 Virus Production
- Preclinical data published in
- Study conducted by Drs.
N.S. Banerjee, L.T. Chowand T.R. Brokerat The University of Alabama at Birmingham
- Findings reinforce anti-viral mechanism of action for Novan’s nitric oxide-based drug substance
- HPV-related clinical applications remain an area of focus for the Company
The preclinical work published in the manuscript demonstrates NVN1000’s durable inhibition of high-risk HPV-18 DNA replication in a three-dimensional human skin culture model. More specifically, the output from the study shows reduction of both the E6 and E7 viral oncoprotein levels.
“The observations published are exciting and highlight both NVN1000’s strong inhibitory effect against HPV when topically delivered to the infected epithelium and its broader anti-viral mechanism of action,” commented the authors of the study. Drs. Broker and Chow further noted, “while there are treatments available today in the HPV arena, none comprise a complete and reliable solution for patients and most have tolerability issues. The in vitro NVN1000 efficacy data that our laboratory has generated provide compelling evidence to invest the effort and resources to pursue additional clinical development activities which target premalignant HPV lesions.
”Title: “NVN1000, a novel nitric oxide-releasing compound, inhibits HPV-18 virus production by interfering with E6 and E7 oncoprotein functions”
The in vitro results suggest that the positive results seen during the Phase 2 clinical trial with SB206 for the treatment of external genital warts caused by HPV could be due to the direct antiviral activity of NVN1000 against HPV proteins.
About Human Papillomavirus (HPV)
HPV refers to a large family of double-stranded DNA viruses that induce abnormal growths on the skin or mucosal surfaces. HPV affects nearly 80 million Americans, and an estimated 14 million new cases of the virus are reported each year, according to the
This press release contains forward-looking statements including, but not limited to, statements related to pharmaceutical development of nitric oxide-releasing product candidates, our intention to advance development of nitric oxide-releasing product candidates and the future prospects of our business and our product candidates. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations, including, but not limited to, risks and uncertainties in the clinical development process, including, among others, length, expense, ability to enroll patients, reliance on third parties, potential for delays and that results of earlier research and preclinical or clinical trials may not be predictive of results, conclusions or interpretations of later research activities or additional trials; risks related to the regulatory approval process, which is lengthy, time-consuming and inherently unpredictable, including the risk that our product candidates may not be approved or that additional studies may be required for approval or other delays may occur and that we may not obtain funding sufficient to complete the regulatory or development process; our ability to obtain additional funding or enter into strategic relationships or other business development necessary for the further development of our product candidates, including the amount and timing of any grants to support funding for a women’s health product candidate; and other risks and uncertainties described in our annual report filed with the
(Investors & Media)
Director, Investor Relations, Communications & Business Development
Source: Novan, Inc.